CBB1007

Overview

CBB1007 is a reversible and selective LSD1 inhibitor with an IC 50 of 5.27 µM for human LSD1. CBB1007 significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Signaling Pathways > Histone Demethylase

Product Information

• Catalog No.: HY-15313
• CAS No.: 1379573-92-8
• Molecular Formula: C27H34N8O4
• Molecular Weight: 534.61
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source